Sanofi SA (EPA:SAN) has been given a €90.00 ($105.88) target price by analysts at J P Morgan Chase & Co in a research note issued on Tuesday, August 1st. The firm presently has a “neutral” rating on the stock.
A number of other equities analysts have also recently weighed in on SAN. Berenberg Bank set a €92.00 ($108.24) price objective on shares of Sanofi SA and gave the company a “buy” rating in a research report on Friday, April 28th. Morgan Stanley set a €91.00 ($107.06) price target on shares of Sanofi SA and gave the stock a “buy” rating in a research report on Monday, April 24th. Kepler Capital Markets set a €92.00 ($108.24) price target on shares of Sanofi SA and gave the stock a “buy” rating in a research report on Wednesday, April 12th. Deutsche Bank AG set a €96.00 ($112.94) target price on shares of Sanofi SA and gave the stock a “buy” rating in a report on Tuesday, April 11th. Finally, Credit Suisse Group set a €95.00 ($111.76) target price on shares of Sanofi SA and gave the stock a “buy” rating in a report on Tuesday, July 4th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of €87.63 ($103.09).
Sanofi SA (EPA:SAN) traded down 0.25% during midday trading on Tuesday, reaching €80.60. The company had a trading volume of 2,300,135 shares. The firm has a 50-day moving average of €25.48 and a 200 day moving average of €25.74. Sanofi SA has a 1-year low of €62.50 and a 1-year high of €92.97. The company has a market capitalization of €101.21 billion and a P/E ratio of 11.24.
TRADEMARK VIOLATION NOTICE: This story was first posted by Stock Observer and is the property of of Stock Observer. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.thestockobserver.com/2017/08/12/sanofi-sa-epasan-given-a-90-00-price-target-at-j-p-morgan-chase-co-updated.html.
About Sanofi SA
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.